Cargando…

Fluorescent hiPSC-derived MYH6-mScarlet cardiomyocytes for real-time tracking, imaging, and cardiotoxicity assays

Human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) hold great potential in the cardiovascular field for human disease modeling, drug development, and regenerative medicine. However, multiple hurdles still exist for the effective utilization of hiPSC-CMs as a human-based experimen...

Descripción completa

Detalles Bibliográficos
Autores principales: Maria Cherian, Reeja, Prajapati, Chandra, Penttinen, Kirsi, Häkli, Martta, Koivisto, Janne T., Pekkanen-Mattila, Mari, Aalto-Setälä, Katriina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042918/
https://www.ncbi.nlm.nih.gov/pubmed/35870039
http://dx.doi.org/10.1007/s10565-022-09742-0
_version_ 1784913035835473920
author Maria Cherian, Reeja
Prajapati, Chandra
Penttinen, Kirsi
Häkli, Martta
Koivisto, Janne T.
Pekkanen-Mattila, Mari
Aalto-Setälä, Katriina
author_facet Maria Cherian, Reeja
Prajapati, Chandra
Penttinen, Kirsi
Häkli, Martta
Koivisto, Janne T.
Pekkanen-Mattila, Mari
Aalto-Setälä, Katriina
author_sort Maria Cherian, Reeja
collection PubMed
description Human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) hold great potential in the cardiovascular field for human disease modeling, drug development, and regenerative medicine. However, multiple hurdles still exist for the effective utilization of hiPSC-CMs as a human-based experimental platform that can be an alternative to the current animal models. To further expand their potential as a research tool and bridge the translational gap, we have generated a cardiac-specific hiPSC reporter line that differentiates into fluorescent CMs using CRISPR-Cas9 genome editing technology. The CMs illuminated with the mScarlet fluorescence enable their non-invasive continuous tracking and functional cellular phenotyping, offering a real-time 2D/3D imaging platform. Utilizing the reporter CMs, we developed an imaging-based cardiotoxicity screening system that can monitor distinct drug-induced structural toxicity and CM viability in real time. The reporter fluorescence enabled visualization of sarcomeric disarray and displayed a drug dose–dependent decrease in its fluorescence. The study also has demonstrated the reporter CMs as a biomaterial cytocompatibility analysis tool that can monitor dynamic cell behavior and maturity of hiPSC-CMs cultured in various biomaterial scaffolds. This versatile cardiac imaging tool that enables real time tracking and high-resolution imaging of CMs has significant potential in disease modeling, drug screening, and toxicology testing. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10565-022-09742-0.
format Online
Article
Text
id pubmed-10042918
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-100429182023-03-29 Fluorescent hiPSC-derived MYH6-mScarlet cardiomyocytes for real-time tracking, imaging, and cardiotoxicity assays Maria Cherian, Reeja Prajapati, Chandra Penttinen, Kirsi Häkli, Martta Koivisto, Janne T. Pekkanen-Mattila, Mari Aalto-Setälä, Katriina Cell Biol Toxicol Research Human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) hold great potential in the cardiovascular field for human disease modeling, drug development, and regenerative medicine. However, multiple hurdles still exist for the effective utilization of hiPSC-CMs as a human-based experimental platform that can be an alternative to the current animal models. To further expand their potential as a research tool and bridge the translational gap, we have generated a cardiac-specific hiPSC reporter line that differentiates into fluorescent CMs using CRISPR-Cas9 genome editing technology. The CMs illuminated with the mScarlet fluorescence enable their non-invasive continuous tracking and functional cellular phenotyping, offering a real-time 2D/3D imaging platform. Utilizing the reporter CMs, we developed an imaging-based cardiotoxicity screening system that can monitor distinct drug-induced structural toxicity and CM viability in real time. The reporter fluorescence enabled visualization of sarcomeric disarray and displayed a drug dose–dependent decrease in its fluorescence. The study also has demonstrated the reporter CMs as a biomaterial cytocompatibility analysis tool that can monitor dynamic cell behavior and maturity of hiPSC-CMs cultured in various biomaterial scaffolds. This versatile cardiac imaging tool that enables real time tracking and high-resolution imaging of CMs has significant potential in disease modeling, drug screening, and toxicology testing. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10565-022-09742-0. Springer Netherlands 2022-07-23 2023 /pmc/articles/PMC10042918/ /pubmed/35870039 http://dx.doi.org/10.1007/s10565-022-09742-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Maria Cherian, Reeja
Prajapati, Chandra
Penttinen, Kirsi
Häkli, Martta
Koivisto, Janne T.
Pekkanen-Mattila, Mari
Aalto-Setälä, Katriina
Fluorescent hiPSC-derived MYH6-mScarlet cardiomyocytes for real-time tracking, imaging, and cardiotoxicity assays
title Fluorescent hiPSC-derived MYH6-mScarlet cardiomyocytes for real-time tracking, imaging, and cardiotoxicity assays
title_full Fluorescent hiPSC-derived MYH6-mScarlet cardiomyocytes for real-time tracking, imaging, and cardiotoxicity assays
title_fullStr Fluorescent hiPSC-derived MYH6-mScarlet cardiomyocytes for real-time tracking, imaging, and cardiotoxicity assays
title_full_unstemmed Fluorescent hiPSC-derived MYH6-mScarlet cardiomyocytes for real-time tracking, imaging, and cardiotoxicity assays
title_short Fluorescent hiPSC-derived MYH6-mScarlet cardiomyocytes for real-time tracking, imaging, and cardiotoxicity assays
title_sort fluorescent hipsc-derived myh6-mscarlet cardiomyocytes for real-time tracking, imaging, and cardiotoxicity assays
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042918/
https://www.ncbi.nlm.nih.gov/pubmed/35870039
http://dx.doi.org/10.1007/s10565-022-09742-0
work_keys_str_mv AT mariacherianreeja fluorescenthipscderivedmyh6mscarletcardiomyocytesforrealtimetrackingimagingandcardiotoxicityassays
AT prajapatichandra fluorescenthipscderivedmyh6mscarletcardiomyocytesforrealtimetrackingimagingandcardiotoxicityassays
AT penttinenkirsi fluorescenthipscderivedmyh6mscarletcardiomyocytesforrealtimetrackingimagingandcardiotoxicityassays
AT haklimartta fluorescenthipscderivedmyh6mscarletcardiomyocytesforrealtimetrackingimagingandcardiotoxicityassays
AT koivistojannet fluorescenthipscderivedmyh6mscarletcardiomyocytesforrealtimetrackingimagingandcardiotoxicityassays
AT pekkanenmattilamari fluorescenthipscderivedmyh6mscarletcardiomyocytesforrealtimetrackingimagingandcardiotoxicityassays
AT aaltosetalakatriina fluorescenthipscderivedmyh6mscarletcardiomyocytesforrealtimetrackingimagingandcardiotoxicityassays